{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910163020803321"]
[null,null,"Titolo",null,"Anti-VEGF / / volume editors, F. Bandello, M. Battaglia Parodi ; co-editors, A.J. Augustin ... [et al.]"]
[null,null,"Pubbl/distr/stampa",null,"Basel ; ; New York, : Karger, c2010"]
[null,null,"ISBN",null,"1-283-15375-0"]
[{"$nulls":4},"9786613153753"]
[{"$nulls":4},"3-8055-9530-1"]
[null,null,"Descrizione fisica",null,"1 online resource (155 p.)"]
[null,null,"Collana",null,"Developments in ophthalmology, , 0250-3751 ; ; v. 46"]
[null,null,"Disciplina",null,"617.7/061"]
[null,null,"Soggetti",null,"Eye - Blood-vessels - Diseases - Chemotherapy"]
[{"$nulls":4},"Vascular endothelial growth factors - Antagonists - Therapeutic use"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and indexes."]
[null,null,"Nota di contenuto",null,"\"\"Cover\"\"; \"\"Contents\"\"; \"\"List of Contributors\"\"; \"\"Preface\"\"; \"\"Angiostatic and Angiogenic Factors\"\"; \"\"Abstract\"\"; \"\"Angiostatic Factors in the Eye\"\"; \"\"Angiogenic Factors\"\"; \"\"Mechanisms of Ocular Angiogenesis and Its Molecular Mediators\"\"; \"\"Abstract\"\"; \"\"Angiogenesis: Mechanisms and Molecular Mediators\"\"; \"\"Retinal Circulation\"\"; \"\"Pathological Ocular Angiogenesis\"\"; \"\"References\"\"; \"\"Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration\"\"; \"\"Abstract\"\"; \"\"Pegaptanib\"\"; \"\"Bevacizumab\"\"; \"\"Ranibizumab\"\"; \"\"PIER Study\"\"; \"\"FOCUS Study\"\"; \"\"MARINA Study\"\""]
[{"$nulls":4},"\"\"ANCHOR Study\"\"\"\"PrONTO Study\"\"; \"\"New Anti-VEGF Treatments for Neovascular Age-Related Macular Degeneration\"\"; \"\"Imaging Anti-VEGF Effects on Retinal Morphology in Age-Related Macular Degeneration\"\"; \"\"References\"\"; \"\"Antivascular Endothelial Growth Factor in Diabetic Retinopathy\"\"; \"\"Abstract\"\"; \"\"Role of the Vascular Endothelial Growth Factor in Diabetic Retinopathy\"\"; \"\"Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema and Proliferative Diabetic Retinopathy\"\"; \"\"Ranibizumab\"\"; \"\"Pegaptanib\"\"; \"\"Bevacizumab\"\"; \"\"VEGF Trap\"\"; \"\"Bevasiranib\"\"; \"\"Rapamycin\"\"; \"\"Conclusion\"\""]
[{"$nulls":4},"\"\"References\"\"\"\"Retinal Vein Occlusions\"\"; \"\"Abstract\"\"; \"\"Background\"\"; \"\"Pathogenesis and Risk Factors\"\"; \"\"Symptoms and Natural Course\"\"; \"\"Treatment of RVO\"\"; \"\"Conclusion\"\"; \"\"References\"\"; \"\"Antivascular Endothelial Growth Factor for Choroidal Neovascularization in Pathologic Myopia\"\"; \"\"Abstract\"\"; \"\"Natural History\"\"; \"\"Treatment "]
[{"$nulls":4},"Options\"\"; \"\"Anti-VEGF for Myopic CNV\"\"; \"\"Subfoveal Myopic CNV\"\"; \"\"Juxtafoveal Myopic CNV\"\"; \"\"References\"\"; \"\"Antivascular Endothelial Growth Factors for Inflammatory Chorioretinal Disorders\"\"; \"\"Abstract\"\""]
[{"$nulls":4},"\"\"Multifocal Choroiditis and Punctate Inner Choriodopathy\"\"\"\"Ocular Histoplasmosis Syndrome\"\"; \"\"BehÃetâ€?s Disease\"\"; \"\"Multiple Evanescent White Dot Syndrome\"\"; \"\"Birdshot Chorioretinopathy\"\"; \"\"Acute Multifocal Posterior Placoid Pigment Epitheliopathy\"\"; \"\"Serpiginous Choroiditis\"\"; \"\"Persistent Placoid Maculopathy\"\"; \"\"Uveitic Cystoid Macular Edema\"\"; \"\"Conclusions\"\"; \"\"References\"\"; \"\"Antivascular Endothelial Growth Factor Treatment in Pseudoxanthoma Elasticum Patients\"\"; \"\"Abstract\"\"; \"\"History and General Disease\"\"; \"\"Genetics of PXE\"\"; \"\"Ocular Signs and Symptoms of PXE\"\""]
[{"$nulls":4},"\"\"Treatment of CNV\"\"\"\"Conclusions\"\"; \"\"References\"\"; \"\"Antivascular Endothelial Growth Factor in Hereditary Dystrophies\"\"; \"\"Abstract\"\"; \"\"Bestâ€?s Dystrophy\"\"; \"\"Pattern Dystrophy\"\"; \"\"Retinitis Pigmentosa\"\"; \"\"Fundus Flavimaculatus\"\"; \"\"Sorsby Fundus Dystrophy\"\"; \"\"References\"\"; \"\"Antivascular Endothelial Growth Factor as an Approach for Macular Edema\"\"; \"\"Abstract\"\"; \"\"Basic Pathophysiologic Mechanisms\"\"; \"\"Major Pathologic Conditions Leading to ME: Retinal Vascular Disease\"\"; \"\"Pharmacologic Treatment Options in ME with a Focus on Anti-VEGF Therapies\"\"; \"\"ME Secondary to CRVO and BRVO\"\""]
[{"$nulls":4},"\"\"References\"\""]
[null,null,null,"Sommario/riassunto","The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.    Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.  The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists."]